Year: 2016 | Month: June | Volume 5 | Issue 1
Kala-Azar- Treatment Update
Abstract:
The sparse treatment options in Visceral Leishmaniasis (VL) makes its treatment very challenging. Long treatment duration and toxic adverse effect of anti-lesihmanial drugs further add to the problem of effective management. As still no effective vaccine is available, the sole treatment of VL is only based on anti-lesihmanial drugs. Also the increasing resistance to existing drugs also pose a hurdle to VL treatment. In Indian sub-continent, single dose of liposomal amphotericin B (L-AmB) and multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin (PM), or miltefosine + PM) are the treatment of choice for VL.
© This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Print This Article Email This Article to Your Friend
